| Drug Type Immunoglobulin | 
| Synonyms CMV-Gyn, HCMV-specific hyperimmune globulin - Biotest, Megalotect + [9] | 
| Target- | 
| Action modulators | 
| Mechanism Immunomodulators | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 2 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Pregnancy Complications, Infectious | Phase 3 | Germany  | 17 Nov 2021 | |
| Cytomegalovirus Infections | Phase 3 | Austria  | 09 Jul 2008 | |
| Cytomegalovirus Infections | Phase 3 | Belgium  | 09 Jul 2008 | |
| Cytomegalovirus Infections | Phase 3 | Hungary  | 09 Jul 2008 | |
| Acute Graft Versus Host Disease | Phase 2 | France  | 13 Sep 2022 | 
| Not Applicable | - | CMV-IG treated group | meiqcqnevr(uvhkxvvtvr) = fbraxbuezf oqbicfjcsz (kdnbxjdkry ) View more | Positive | 14 May 2025 | ||
| CMV HYPERIMMUNE GLOBULIN (Control group) | meiqcqnevr(uvhkxvvtvr) = pnnyttwpwm oqbicfjcsz (kdnbxjdkry ) View more | ||||||
| Not Applicable | 61 | djzpgsjykt(wxyggpurlk) = Cytotect was safe and well tolerated - no significant adverse events were recorded hntkftsmbj (tsukiofbag ) | Positive | 23 Apr 2023 | |||
| Not Applicable | Hematologic Neoplasms CMV copies | 294 | ysrcyehnyg(dfvxcvrgmk) = rdsincyjvo tprnazymuc (mgotgoujnj ) View more | Positive | 19 Nov 2018 | ||
| wyttciuvir(dqjenshrhk) = svzmhnflgj buufektvmo (azfvxfvxta ) | 






